Palvella Therapeutics (NASDAQ:PVLA) Given Buy Rating at HC Wainwright

Palvella Therapeutics (NASDAQ:PVLA)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $38.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 166.67% from the company’s previous close.

Separately, Cantor Fitzgerald assumed coverage on Palvella Therapeutics in a research note on Wednesday, December 18th. They set an “overweight” rating on the stock.

Palvella Therapeutics Stock Down 3.3 %

Shares of PVLA stock opened at $14.25 on Friday. The firm has a market capitalization of $18.81 million, a price-to-earnings ratio of -1.18 and a beta of 0.67. Palvella Therapeutics has a 52-week low of $6.20 and a 52-week high of $22.32.

Insider Buying and Selling

In other news, Director George M. Jenkins bought 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The shares were bought at an average cost of $12.93 per share, for a total transaction of $51,720.00. Following the completion of the transaction, the director now owns 180,671 shares of the company’s stock, valued at approximately $2,336,076.03. This represents a 2.26 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 6.39% of the stock is owned by company insiders.